Evidence map›Paper›PMID 41957754›Full record

ArticleBioData mining2026

Prognostic biomarker discovery in pancreatic cancer through hybrid ensemble feature selection and multi-omics data.

John Zobolas, Anne-Marie George, Alberto López, Sebastian Fischer, Marc Becker, Tero Aittokallio

Abstract read
In one paragraph

Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

John ZobolasDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. bblodfon@gmail.com.ORCID http://orcid.org/0000-0002-3609-8674
Anne-Marie GeorgeDepartment of Informatics, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0001-9232-8211
Alberto LópezOslo Centre for Biostatistics and Epidemiology (OCBE), Department of Biostatistics, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-9039-7042
Sebastian FischerDepartment of Statistics, Ludwig Maximilian University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9609-3197
Marc BeckerDepartment of Statistics, Ludwig Maximilian University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-8115-0400
Tero AittokallioDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-0886-9769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate prediction of patient survival using high-dimensional multi-omics data requires effective feature selection methods that balance predictive performance, sparsity, and stability to enable reproducible and transparent prognostic biomarker discovery. Existing approaches often rely on ad hoc thresholds, limiting their reproducibility and clinical utility.

methodsWe developed a hybrid ensemble feature selection (hEFS) framework that integrates data subsampling with multiple prognostic models, combining embedded and wrapper-based strategies for survival prediction. Features are ranked using a voting-theory-inspired aggregation approach across models and subsamples, while the optimal feature subset is determined via Pareto front optimization, eliminating the need for user-defined thresholds. We benchmarked hEFS against conventional CoxLasso using 100 Monte Carlo cross-validation iterations on multi-omics datasets from three pancreatic ductal adenocarcinoma (PDAC) cohorts, assessing sparsity, stability, redundancy, discrimination, and computational cost.

resultsAcross all cohorts, hEFS selected substantially fewer and more stable features than CoxLasso (~10 vs. ~60 per modality), with lower variance, while still maintaining comparable discrimination performance with clinical baselines (C-index ~0.54–0.60). Feature redundancy was low, and ensemble subsampling further improved stability. Prognostic performance depended mainly on modality choice, rather than integration model, with gene expression plus clinical variables achieving the highest discrimination power (C-index ~0.64).

conclusionshEFS provides a fully automated, interpretable, and reproducible framework for multi-omics biomarker discovery in high-dimensional survival analysis. By producing sparse, yet stable biomarker panels without loss of predictive power, hEFS represents a practical tool for integrative multi-omics modeling and it is openly available in the mlr3fselect R package.

Indexed as

Biomarker discoveryEnsemble learningFeature selectionHigh-dimensional dataMachine learningPareto optimizationStability analysisSurvival analysis

Identifiers

PMID41957754
PMCPMC13188360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.